Targeted therapy(Eli Lilly and Company)은 Pneumonitis, Interstitial 표적 치료제로, Gastric Cancer With Liver Metastases 영역에서 개발·상용화 중입니다. 작용기전: targets and cellular pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: 0% (ClinicalTrials.gov NCT03321981). 차별점: novel targeted antidepressant therapies and driving a shift beyond conventional treatment strategies.
Pneumonitis, Interstitial
Gastric Cancer With Liver Metastases
Recruiting
ADC) development
govitecan (SG) and datopotamab deruxtecan (Dato-D
novel targeted antidepressant therapies and driving a shift beyond conventional treatment strategies
targets and cellular pathway
T-cell therapy offer potential for prolonged immune engagement
apoptosis in vitro, and suppressed HCC growth in vivo
biomarkers for targeted therapy
downregulation of this mitochondrial enzyme severely disrupts the metabolic stability required for DTP survival
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Targeted therapy(Eli Lilly and Company)은 Pneumonitis, Interstitial 표적 치료제로, Gastric Cancer With Liver Metastases 영역에서 개발·상용화 중입니다. 작용기전: targets and cellular pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: 0% (ClinicalTrials.gov NCT03321981). 차별점: novel targeted antidepressant therapies and driving a shift beyond conventional treatment strategies.
Pneumonitis, Interstitial
Gastric Cancer With Liver Metastases
Recruiting
ADC) development
govitecan (SG) and datopotamab deruxtecan (Dato-D
novel targeted antidepressant therapies and driving a shift beyond conventional treatment strategies
targets and cellular pathway
T-cell therapy offer potential for prolonged immune engagement
apoptosis in vitro, and suppressed HCC growth in vivo
biomarkers for targeted therapy
downregulation of this mitochondrial enzyme severely disrupts the metabolic stability required for DTP survival
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.